Skip to content
2000
Volume 1, Issue 2
  • ISSN: 2213-476X
  • E-ISSN: 2213-4778

Abstract

Bioavailability and bioequivalence studies play a major role in the drug development phase for both new formulations and their generic equivalents. There are various investigations to assess bioequivalence and each regulatory authority has its own guidance for the conduction of bioavailability and bioequivalence studies before approval of generic products. Bioequivalence studies are the primary needs for generic products to enter in the market. The manufacturer’s (generic product) must be in limit with that of innovator (branded) formulation (reference listed drug). This review deals with methods of bioavailability studies and requirement of bioequivalence studies necessary for filing of data for the approval of formulation.

Loading

Article metrics loading...

/content/journals/acctra/10.2174/2213476X01666140613221900
2014-08-01
2025-07-06
Loading full text...

Full text loading...

/content/journals/acctra/10.2174/2213476X01666140613221900
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test